Obtention of omega-3-fatty acids cryoconcentrated fish oil from by-products of preserves industry

Received: February 24th, 2021 ; Accepted: May 2nd, 2021 ; Published: May 19th, 2021 ; Correspondence: [email protected] technology for obtaining and cryoconcentration of high-quality fish oil from collagen-containing wastes of slightly salted herring under gentle conditions using electrochemically obtained catholytes has been developed. Physicochemical analysis of raw materials was carried out and the yields of products from raw materials at all stages of processing were determined. Concentration of omega-3 fatty acids in oil was carried out using the cryo method. The main phase transitions in oil with decreasing temperature have been determined. The mass yields were determined and the biochemical composition of the cryoconcentrated fish oil fractions was investigated. It was defined the temperature of -14° С at which a phase transition is observed, providing an increase in the concentration of omega-3 fatty acids in oil by 3 times. The usage of cryoconcentrated fish oil allows to produce biologically active food supplement or raw materials for a functional food

The multilevel trigger system of the DIRAC experiment

The multilevel trigger system of the DIRAC experiment at CERN is presented. It includes a fast first level trigger as well as various trigger processors to select events with a pair of pions having a low relative momentum typical of the physical process under study. One of these processors employs the drift chamber data, another one is based on a neural network algorithm and the others use various hit-map detector correlations. Two versions of the trigger system used at different stages of the experiment are described. The complete system reduces the event rate by a factor of 1000, with efficiency $\geq$95% of detecting the events in the relative momentum range of interest.Comment: 21 pages, 11 figure

Diagonalizing operators over continuous fields of C*-algebras

It is well known that in the commutative case, i.e. for $A=C(X)$ being a commutative C*-algebra, compact selfadjoint operators acting on the Hilbert C*-module $H_A$ (= continuous families of such operators $K(x)$, $x\in X$) can be diagonalized if we pass to a bigger W*-algebra $L^\infty(X)={\bf A} \supset A$ which can be obtained from $A$ by completing it with respect to the weak topology. Unlike the "eigenvectors", which have coordinates from $\bf A$, the "eigenvalues" are continuous, i.e. lie in the C*-algebra $A$. We discuss here the non-commutative analog of this well-known fact. Here the "eigenvalues" are defined not uniquely but in some cases they can also be taken from the initial C*-algebra instead of the bigger W*-algebra. We prove here that such is the case for some continuous fields of real rank zero C*-algebras over a one-dimensional manifold and give an example of a C*-algebra $A$ for which the "eigenvalues" cannot be chosen from $A$, i.e. are discontinuous. The main point of the proof is connected with a problem on almost commuting operators. We prove that for some C*-algebras if $h\in A$ is a selfadjoint, $u\in A$ is a unitary and if the norm of their commutant $[u,h]$ is small enough then one can connect $u$ with the unity by a path $u(t)$ so that the norm of $[u(t),h]$ would be also small along this path.Comment: 21 pages, LaTeX 2.09, no figure

Dipeptidyl peptidase-4 (DPP-4) inhibitors effects on the cardiovascular system

The article presents literature review dwelling on the effects of dipeptidyl peptidase-4 (DPP-4) inhibitors hypoglycemic drugs (saxagliptin, alogliptin, sitagliptin, linagliptin, vildagliptin) on cardiovascular outcomes. When comparing these drugs, it was found that dipeptidyl peptidase-4 inhibitors at least didn't increase mortality rate associated with heart failure, except for saxagliptinВ статье представлен литературный обзор данных о влиянии сахароснижающих препаратов группы ингибиторов дипептидилпептидазы 4 типа (саксаглиптина, алоглиптина, ситаглиптина, линаглиптина, вилдаглиптина) в отношении сердечно-сосудистых исходов. Сравнивая данные препараты показано, что ингибиторы дипептидилпептидазы 4 типа по меньшей мере не вызывали повышенной смертности, связанной с сердечной недостаточностью, кроме саксаглиптина